Prices delayed by at least 15 minutes | Print
Takeda Pharmaceutical Company Limited (TAK)
American Depository ReceiptsThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
Address
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo
JPN
103-8668
Telephone
+81 332782543
Forecast key dates
| Name | Key Date |
|---|---|
| Takeda Pharmaceutical Co Ltd Third Quarter Earnings Results for 2025 | 2025-01-31T00:00:00 |
| Takeda Pharmaceutical Co Ltd Second Quarter Earnings Results for 2025 | 2024-10-25T15:00:00 |
| Takeda Pharmaceutical Co Ltd First Quarter Earnings Results for 2025 | 2024-07-26T15:00:00 |
| Takeda Pharmaceutical Co Ltd Annual Report for 2024 | 2024-06-28T00:00:00 |
| Takeda Pharmaceutical Co Ltd Annual General Meeting for 2024 | 2024-06-26T00:00:00 |
| Takeda Pharmaceutical Co Ltd Fourth Quarter Earnings Results for 2024 | 2024-05-10T15:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Takeda Pharmaceutical Co Ltd Fourth Quarter Earnings Results for 2024 | 2024-05-10T15:00:00 |
| Takeda Pharmaceutical Co Ltd Third Quarter Earnings Results for 2024 | 2024-02-01T00:00:00 |
| Takeda Pharmaceutical Co Ltd Second Quarter Earnings Results for 2024 | 2023-10-26T15:00:00 |
| Takeda Pharmaceutical Co Ltd First Quarter Earnings Results for 2024 | 2023-07-27T15:00:00 |
| Takeda Pharmaceutical Co Ltd Annual General Meeting for 2023 | 2023-06-28T00:00:00 |
| Takeda Pharmaceutical Co Ltd Annual Report for 2023 | 2023-06-28T00:00:00 |
| Takeda Pharmaceutical Co Ltd Fourth Quarter Earnings Results for 2023 | 2023-05-11T15:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.